Immutep Ltd Eftilagimod Alpha Clinical Development Update And New Data From Ongoing Melanoma Study Transcript
Okay. Good morning, everyone. Thank you for joining us for another Immutep Investor Call to discuss on the company's lead candidate, eftilagimod alpha. I'm Clive Tomkins here in Sydney. I'll be your moderator today. (Operator Instructions)
I'd now like to hand you over to Marc Voigt, Immutep's CEO, to start the presentation. Over to you, Marc.
Thank you, Clive, and welcome, everyone. We very much appreciate your time on the call today. Our forward-looking statement: We're very pleased to give you an update on our clinical development strategy for our lead product candidate, eftilagimod alpha, also known as efti or IMP321 as well as presenting data from our ongoing melanoma study called TACTI-mel and new updates on our other studies. On the call with me today, we have Professor Frédéric Triebel, who is our CMO and CSO; along with Christian Mueller, our Director Clinical Development and Regulatory Affairs.
Before we dive into the slides, I would
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |